Sunitinib for metastatic renal cell cancer patients: Observational study highlighting the risk of important drug-drug interactions

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 3, 2014, Pages 259-265

  Kruse, V ^a,b   Somers, A ^a   Van Bortel, L ^b   De Both, A ^a   Van Belle, S ^a   Rottey, S ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

adverse drug reactions; comedications; drug drug interactions; metastatic renal cell cancer; sunitinib

Indexed keywords

ATAZANAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARBAMAZEPINE; CLARITHROMYCIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOMPERIDONE; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPERAMIDE; METOCLOPRAMIDE; NEFAZODONE; NELFINAVIR; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SUNITINIB; TELITHROMYCIN; VORICONAZOLE; ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PYRROLE DERIVATIVE;

ADULT; ANOREXIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART VENTRICLE ARRHYTHMIA; HEARTBURN; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; RETROSPECTIVE STUDY; TASTE DISORDER; THROMBOCYTOPENIA; WEIGHT REDUCTION; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG INTERACTION; KIDNEY NEOPLASMS; MIDDLE AGED; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899451245     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12134     Document Type: Article

References (23)

1. Gupta K, Miller JD, Li JZ, et al,. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev, 2008; 34: 195-205.
2. Levi F, Ferlay J, Galeone C, et al,. The changing pattern of kidney cancer incidences and mortality in Europe. BJU Int, 2008; 101: 945-958.
3. Eble JN, Sauter G, Epstein JI, Sesterhenn I, (eds.) In: Pathology and genetics of tumours of the urinary system and male genital organs. World health organisation classification of tumours. Lyons: IARC Press, 2004, 7.
4. Nathanson KL, Stephenson AJ,. Diagnosis and management of inherited renal cancer. In:, Rini BI, Campbell SC, eds. Renal cell cancer. Shelton, CT: Peoples Medical Publishing House, 25-40, 2006.
5. Kaelin WG Jr,. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res, 2007; 13: 680s-684s.
6. Figlin RA, Hutson TE, Tomczak P, et al,. Overall survival with sunitinib versus (IFN)-alfa as first line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2008; 26: 256s. (suppl. abstr 5024).
7. Motzer RJ, Hutson TE, Tomczak P, et al,. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009; 27: 3584-3590.
8. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med, 2007; 356: 115-124.
9. Full Prescribing information on SUTENT Available at: www.sutent.com (accessed January 2011).
10. Oudard S, Beuselinck B, Decoene J, et al,. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev, 2011; 37: 178-184.
11. Motzer RJ, Hutson TE, Olsen MR, et al,. Randomized Phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 schedule vs continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma (Renal EFFECT Trial). Oral presentation at the 2011 American Society of Clinical Oncology Genitourinary Cancer Symposium, Orlando, FL, USA, February 17-19, 2011 (abstract 308).
12. Shukla S, Robey RW, Bates SE, Ambudkar SV,. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters Pg glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos, 2009; 37: 359-365. Epub 2008 Oct 29.
13. van Leeuwen RW, Brundel DH, Neef C, et al,. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer, 2013; 108: 1071-1078.
14. van Leeuwen RW, Swart EL, Boven E, et al,. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol, 2011; 22: 2334-2341.
15. Khosravan R, Huang X, Wiltshire R, et al,. A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): pitfalls of efficacy subgroup analyses based on dose-reduction status. J Clin Oncol, 2012; 30 (suppl 5; abst 363).
16. Escudier B, Kataja V,. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO guidelines working group. Ann Oncol, 2010; 21 (Suppl 5): v137-v139.
17. Lameire N, Kruse V, Rottey S,. Nephrotoxicity of anticancer drugs-an underestimated problem?. Acta Clin Belg, 2011; 66: 337-345.
18. Rini BI, Cohen DP, Chen I, et al,. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 2011; 103: 763-773. Epub 2011 Apr 28.
19. Rogiers A, Wolter P, Op de Beeck K, et al,. Shrinkage of thyroid volume in sunitinib-treated patients with renal cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid, 2010; 20: 317-322.
20. Wolter P, Stefan C, Decallone B, et al,. The clinical implantation of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer, 2008; 99: 448-454.
21. Garfield DH, Hercbergs A, Davis PJ,. Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 2007; 99: 975-976.
22. Mountford CM, Lee T, Lemos J, et al,. Quality and usability of common drug information databases. Can J Hosp Pharm, 2010; 63: 130-137.
23. Clauson KA, Marsh WA, Polen HH, Seamon MJ, Ortiz BI,. Clinical decision support tools: analysis of online drug information databases. BMC Med Inform Decis Mak, 2007; 8: 7.